Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-d5 dose escalation in NHL and AML
NCT04500587Phase 1Completed
- Sponsor
- Zentalis Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of asaretoclax in non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML) (2 cohorts), sponsored by Zentalis Pharmaceuticals. Primary endpoints: Observed Dose Limiting Toxicities and Incidence and severity of Adverse Events. Started Oct 2020; status: completed.
02
Drugs
asaretoclax
03
Conditions
non-Hodgkin lymphoma (NHL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04500587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04500587.